Initial Statement of Beneficial Ownership (3)
February 19 2020 - 6:01PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Nikolopoulos Nicholas |
2. Date of Event Requiring Statement (MM/DD/YYYY)
2/13/2020
|
3. Issuer Name and Ticker or Trading Symbol
MEDNAX, INC. [MD]
|
(Last)
(First)
(Middle)
1301 CONCORD TERRACE |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director _____ 10% Owner ___X___ Officer (give title below) _____ Other (specify below) EVP Chf Strategy & Growth Offi / |
(Street)
SUNRISE, FL 33323
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY)
| 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Common Stock | 87033 (1) | D | |
Common Stock | 48095 (2) | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 4) | 2. Date Exercisable and Expiration Date (MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Explanation of Responses: |
(1) | Restricted shares granted pursuant to the Issuer's Amended and Restated 2008 Incentive Compensation Plan (the "Plan") as an inducement grant in connection with the hiring of the Reporting Person in February 2019, by the Issuer. The Restricted shares will vest one-third on March 1, 2021 and two-thirds on March 1, 2022 subject to the terms of the Plan. |
(2) | Restricted shares granted pursuant to the Plan in connection with the Reporting Person's annual equity award. The number of shares being reported represents the "target" number of restricted shares and does not include the right of the reporting person to receive up to 12,024 additional shares based on the achievement of certain performance-based criteria for the twelve months ending December 31, 2020. The actual number of shares earned could be less than or greater than the target number, depending on the level of performance achieved, and all of the restricted shares granted are subject to forfeiture if minimum levels of performance are not met. Any restricted shares earned will not vest any earlier than in three equal installments on March 1, 2021, March 1, 2022 and March 1, 2023, subject to the terms of the Plan. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Nikolopoulos Nicholas 1301 CONCORD TERRACE SUNRISE, FL 33323 |
|
| EVP Chf Strategy & Growth Offi |
|
Signatures
|
/s/ Dominic J. Andreano, Attorney-in-Fact | | 2/19/2020 |
**Signature of Reporting Person | Date |
Pediatrix Medical (NYSE:MD)
Historical Stock Chart
From May 2024 to Jun 2024
Pediatrix Medical (NYSE:MD)
Historical Stock Chart
From Jun 2023 to Jun 2024